Skip to content
NewsBlazeAU – Lifestyle
Author:
JenaValve Technology, Inc.
JenaValve Appoints Tonya Porter as Vice President of Regulatory Affairs
May 20, 2026
JenaValve Appoints Dave Haan as Vice President of Clinical Affairs
May 12, 2026
JenaValve Announces the Start of Commercialization of the Trilogy® Transcatheter Heart Valve System in the United States – the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR)
April 1, 2026
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System — the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) in the United States
March 18, 2026